Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally

Phase 2

Completed

Conditions: Multiple Myeloma

First Posted Date: 2004-05-27

Last Posted Date: 2010-07-07

Lead Sponsor: University of Arkansas

Target Recruit Count: 40

Registration Number: NCT00083538

Locations: 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Thalidomide
Drug: Ara-C
Drug: BCNU
Drug: Cytoxan
Drug: Cisplatin
Drug: Dexamethasone
Drug: Doxorubicin
Drug: Etoposide
Drug: Filgrastim
Drug: Recombinant GM-CSF
Drug: Interferon-alpha-2b
Drug: Melphalan
Drug: Vincristine

First Posted Date: 2004-05-27

Last Posted Date: 2015-11-23

Lead Sponsor: University of Arkansas

Target Recruit Count: 668

Registration Number: NCT00083551

Locations: 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States

Bone Marrow Transplantation in Treating Patients With Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: Recombinant Interferon Alfa
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Mesna
Procedure: Bone Marrow Transplantation
Radiation: Radiation Therapy

First Posted Date: 2004-05-26

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 45

Registration Number: NCT00002829

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease

Phase 3

Completed

Conditions: Cardiac Toxicity
Lymphoma

Interventions: Biological: bleomycin sulfate
Biological: filgrastim
Drug: dexrazoxane hydrochloride
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: vincristine sulfate
Radiation: low-LET cobalt-60 gamma ray therapy
Radiation: low-LET electron therapy
Radiation: low-LET photon therapy

First Posted Date: 2004-05-26

Last Posted Date: 2013-08-26

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 294

Registration Number: NCT00002827

Locations: 🇺🇸
Children's Hospital of Columbus, Columbus, Ohio, United States
🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸
Long Beach Memorial Medical Center, Long Beach, California, United States

and more 36 locations

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

Phase 3

Completed

Conditions: Lymphoma
Cardiac Toxicity

Interventions: Biological: bleomycin sulfate
Biological: filgrastim
Drug: cyclophosphamide
Drug: dexrazoxane hydrochloride
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: prednisone
Drug: vincristine sulfate
Radiation: radiation therapy

First Posted Date: 2004-05-26

Last Posted Date: 2014-07-24

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 219

Registration Number: NCT00005578

Locations: 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Simmons Cancer Center - Dallas, Dallas, Texas, United States

and more 60 locations

Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer

Phase 2

Completed

Conditions: Leukemia
Lymphoma
Oral Complications

First Posted Date: 2004-05-25

Last Posted Date: 2013-06-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 111

Registration Number: NCT00004061

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Amifostine, Chemotherapy, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Drug/Agent Toxicity by Tissue/Organ
Radiation Toxicity
Lung Cancer

First Posted Date: 2004-05-25

Last Posted Date: 2013-05-16

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 34

Registration Number: NCT00004176

Locations: 🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸
Washington University Barnard Cancer Center, Saint Louis, Missouri, United States
🇺🇸
Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States

and more 1 locations